| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 3.454 | 5.607 | 6.026 | 4.376 | 2.024 | 2.233 | 0 |
| Total Income - EUR | - | - | - | 3.454 | 5.607 | 6.026 | 4.376 | 2.024 | 2.233 | 0 |
| Total Expenses - EUR | - | - | - | 6.082 | 7.506 | 2.242 | 3.406 | 2.922 | 1.570 | 0 |
| Gross Profit/Loss - EUR | - | - | - | -2.629 | -1.900 | 3.784 | 970 | -898 | 663 | 0 |
| Net Profit/Loss - EUR | - | - | - | -2.663 | -1.975 | 3.603 | 839 | -958 | 641 | 0 |
| Employees | - | - | - | 2 | 1 | 1 | 1 | 0 | 1 | 0 |
Check the financial reports for the company - Stage Valmed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | 6.135 | 197 | 2.735 | 625 | 24 | 0 | 0 |
| Inventories | - | - | - | 3.086 | 200 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 2.606 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | - | - | - | 442 | -3 | 2.735 | 625 | 24 | 0 | 0 |
| Shareholders Funds | - | - | - | -2.620 | -4.544 | -855 | 3 | -955 | -311 | -310 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 8.755 | 4.741 | 3.590 | 623 | 980 | 312 | 310 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "5630 - 5630" | |||||||||
| CAEN Financial Year |
5630
|
|||||||||
Comments - Stage Valmed S.r.l.